TWI815061B - 作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法 - Google Patents

作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法 Download PDF

Info

Publication number
TWI815061B
TWI815061B TW109141315A TW109141315A TWI815061B TW I815061 B TWI815061 B TW I815061B TW 109141315 A TW109141315 A TW 109141315A TW 109141315 A TW109141315 A TW 109141315A TW I815061 B TWI815061 B TW I815061B
Authority
TW
Taiwan
Prior art keywords
methyl
trifluoromethyl
pyrimidin
compound
tautomer
Prior art date
Application number
TW109141315A
Other languages
English (en)
Chinese (zh)
Other versions
TW202132317A (zh
Inventor
馬修 保羅 鮑比優
珍妮佛 瑞貝卡 艾蓮
安娜 艾蓮娜 米那提
保羅 溫西蒂
米歇拉 貝爾特拉尼
特奧多拉 達米亞諾娃
伊安 霖嘉德
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202132317A publication Critical patent/TW202132317A/zh
Application granted granted Critical
Publication of TWI815061B publication Critical patent/TWI815061B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW109141315A 2019-11-25 2020-11-25 作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法 TWI815061B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
US62/939,821 2019-11-25

Publications (2)

Publication Number Publication Date
TW202132317A TW202132317A (zh) 2021-09-01
TWI815061B true TWI815061B (zh) 2023-09-11

Family

ID=73855555

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109141315A TWI815061B (zh) 2019-11-25 2020-11-25 作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法
TW112142068A TWI867822B (zh) 2019-11-25 2020-11-25 作為δ-5去飽和酶抑制劑的雜環化合物以及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112142068A TWI867822B (zh) 2019-11-25 2020-11-25 作為δ-5去飽和酶抑制劑的雜環化合物以及使用方法

Country Status (21)

Country Link
US (3) US11512097B2 (enExample)
EP (1) EP4065223A1 (enExample)
JP (2) JP7254246B2 (enExample)
KR (2) KR102598203B1 (enExample)
CN (2) CN118161500A (enExample)
AR (1) AR120556A1 (enExample)
AU (1) AU2020392087B2 (enExample)
BR (1) BR112022010054A2 (enExample)
CA (1) CA3162281A1 (enExample)
CL (2) CL2022001357A1 (enExample)
CO (1) CO2022008690A2 (enExample)
CR (1) CR20220308A (enExample)
IL (1) IL293191B2 (enExample)
JO (1) JOP20220125A1 (enExample)
MX (1) MX2022006281A (enExample)
PE (1) PE20231097A1 (enExample)
PH (1) PH12022551282A1 (enExample)
SA (1) SA522432710B1 (enExample)
TW (2) TWI815061B (enExample)
UY (1) UY38971A (enExample)
WO (1) WO2021108408A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CN118161500A (zh) 2019-11-25 2024-06-11 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
WO2024112763A1 (en) 2022-11-23 2024-05-30 Amgen Inc. Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
EP0242690B1 (en) 1986-04-07 1993-06-30 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
JP2002514196A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジノンおよびピリドン化合物ならびに使用方法
WO2001029044A1 (en) 1999-10-15 2001-04-26 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2003106435A1 (en) 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
AR049769A1 (es) 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
JP5118975B2 (ja) 2004-12-24 2013-01-16 アストラゼネカ・アクチエボラーグ Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
EP1910373A1 (de) 2005-07-27 2008-04-16 Basf Se Fungizide 6-phenyl-triazolopyrimidinylamine
EP1909580A1 (de) 2005-07-27 2008-04-16 Basf Se Fungizide 5-methyl-6-phenyl-triazolopyrimidinylamine
WO2007012601A1 (de) 2005-07-27 2007-02-01 Basf Aktiengesellschaft Fungizide 6-phenyl-pyrazolopyrimidin-7-ylamine
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
WO2008037459A1 (en) 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
CA2665476A1 (en) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
WO2008057601A2 (en) 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
EP2066177B1 (de) 2007-01-19 2014-12-24 Basf Se Fungizide mischungen aus 1-methylpyrazol-4-ylcarbonsäureaniliden und azolopyrimidinylaminen
EP2131658A2 (en) 2007-01-30 2009-12-16 Basf Se Method for improving plant health
US8461077B2 (en) 2007-03-23 2013-06-11 Basf Se Combinations of active substances
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2009124259A1 (en) 2008-04-04 2009-10-08 Cv Therapeutics, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
WO2010087467A1 (en) 2009-01-27 2010-08-05 Takeda Pharmaceutical Company Limited Delta-5-desaturase inhibitors
CN102482278B (zh) 2009-06-29 2015-04-22 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2012011592A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2013177538A2 (en) 2012-05-24 2013-11-28 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
CA2922925A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
EP3683222B1 (en) 2014-04-23 2021-10-06 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
US11414385B2 (en) 2015-12-21 2022-08-16 The University Of Chicago Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
MA46092A (fr) 2016-08-31 2021-04-21 Agios Pharmaceuticals Inc Inhibiteurs de processus métaboliques cellulaires
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN106749271B (zh) * 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
WO2018213365A1 (en) 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MA50256A (fr) 2017-09-15 2020-07-22 Aduro Biotech Inc Composés de pyrazolopyrimidinone et leurs utilisations
CN118161500A (zh) 2019-11-25 2024-06-11 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists

Also Published As

Publication number Publication date
JOP20220125A1 (ar) 2023-01-30
CR20220308A (es) 2022-08-04
CA3162281A1 (en) 2021-06-03
UY38971A (es) 2021-06-30
CL2023002486A1 (es) 2024-01-12
KR20220106159A (ko) 2022-07-28
JP2022549739A (ja) 2022-11-28
CO2022008690A2 (es) 2022-06-30
US11512097B2 (en) 2022-11-29
CN118161500A (zh) 2024-06-11
CL2022001357A1 (es) 2023-03-10
US20210188874A1 (en) 2021-06-24
AU2020392087B2 (en) 2025-10-23
KR102598203B1 (ko) 2023-11-03
TW202132317A (zh) 2021-09-01
JP7254246B2 (ja) 2023-04-07
PE20231097A1 (es) 2023-07-18
US20210221824A1 (en) 2021-07-22
IL293191B2 (en) 2025-09-01
JP2023078418A (ja) 2023-06-06
TWI867822B (zh) 2024-12-21
TW202409042A (zh) 2024-03-01
SA522432710B1 (ar) 2025-05-29
WO2021108408A1 (en) 2021-06-03
CN114728167B (zh) 2024-03-19
MX2022006281A (es) 2022-06-08
IL293191B1 (en) 2025-05-01
AU2020392087A1 (en) 2022-06-09
BR112022010054A2 (pt) 2022-08-16
US12448396B2 (en) 2025-10-21
EP4065223A1 (en) 2022-10-05
CN114728167A (zh) 2022-07-08
IL293191A (en) 2022-07-01
JP7698676B2 (ja) 2025-06-25
KR20230154292A (ko) 2023-11-07
AR120556A1 (es) 2022-02-23
US20230159560A1 (en) 2023-05-25
PH12022551282A1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
TWI815061B (zh) 作為δ-５去飽和酶抑制劑的雜環化合物以及使用方法
US10005774B2 (en) Syk inhibitors
JP5992096B2 (ja) Ｐｄｅ１０阻害剤としてのトリアゾロ化合物
HUE028555T2 (en) Pyrazolinquinoline Derivatives as PDE9 Inhibitors
WO2023091726A1 (en) Inhibitors of cyclin‑dependent kinase 12 (cdk12)
JP2019534324A (ja) Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン
US12473289B2 (en) Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
EA048401B1 (ru) Гетероциклические соединения в качестве ингибиторов дельта-5-десатуразы и способы применения
HK1224672A1 (en) Syk inhibitors
HK1224672B (en) Syk inhibitors